Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03463265 · ClinicalTrials.gov registry record · Phase 2
Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma
A Phase 2 study of High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma, sponsored by Aadi Bioscience.
- Completed
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
- 3
- Study locations
NCT03463265 is a Phase 2 study of High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma that has completed, run by Aadi Bioscience. The registered enrollment target is 62 participants. The trial reports 3 study locations across 1 state.
The verdict
NCT03463265, a Phase 2 study of High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma, has completed, sponsored by Aadi Bioscience.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
- 3
- Study locations
Study Summary
Phase 2, open-label study of nab-sirolimus in patients with recurrent high grade glioma following prior therapy and patients with newly diagnosed glioblastoma. nab-Sirolimus was administered as single agent or in combination therapies.
Conditions Studied
Interventions
- DRUG nab-sirolimus
- DRUG nab-sirolimus + temozolomide
- DRUG nab-sirolimus + bevacizumab
- DRUG nab-sirolimus + lomustine
- DRUG nab-sirolimus + marizomib (MRZ)
Study Locations (3)
California
- St. Joseph Heritage Healthcare - Fullerton
- Hoag Memorial Hospital Presbyterian - Newport Beach
- John Wayne Cancer Institute - Santa Monica
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2018-08-01 |
| Est. Completion | 2022-08-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03463265
The ClinicalTrials.gov registry entry for NCT03463265 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aadi Bioscience, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma appearing as the primary indexed condition, and to 5 interventions - of which nab-sirolimus is the first listed.
NCT03463265 reports 3 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03463265 about?
NCT03463265 is a clinical study titled "Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma". Phase 2, open-label study of nab-sirolimus in patients with recurrent high grade glioma following prior therapy and patients with newly diagnosed glioblastoma. nab-Sirolimus was administered as single agent or in combination therapies.
What is the current status of trial NCT03463265?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2018-08-01. Estimated completion is 2022-08-26.
What conditions does trial NCT03463265 study?
This clinical trial studies the following conditions: High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma.
What interventions are being tested in trial NCT03463265?
The interventions under investigation include: nab-sirolimus (DRUG), nab-sirolimus + temozolomide (DRUG), nab-sirolimus + bevacizumab (DRUG), nab-sirolimus + lomustine (DRUG), nab-sirolimus + marizomib (MRZ) (DRUG).
Who is sponsoring clinical trial NCT03463265?
This trial is sponsored by Aadi Bioscience, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03463265 being conducted?
This trial has 3 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.